GAAP revenue of $14.2 million for Q2 2025 beat analyst estimates and Revenue more than doubled year over year in the second quarter, beating analyst estimates. Net loss per share (GAAP) narrowed to ...

Intellia Therapeutics, Inc. NTLA announced that it has initiated the pivotal phase III HAELO study evaluating NTLA-2002 for the treatment of hereditary angioedema (HAE). The global double-blind ...

Intellia Therapeutics has reported positive results from its ongoing Phase I/II trial of NTLA-2002, a CRISPR-based gene editing therapy for hereditary angioedema (HAE). NTLA-2002, which leverages ...

NTLA-2002 has received five notable regulatory designations, including Orphan Drug and RMAT Designation by the U.S. Food and Drug Administration, the Innovation Passport by the U.K. Medicines and ...

About the NTLA-2002 Clinical Program Intellia’s global Phase 1/2 study is evaluating the safety, tolerability, activity, pharmacokinetics and pharmacodynamics of NTLA-2002 in adults with Type I ...

Intellia has already been able to establish proof of concept in using NTLA-2002 for HAE and then NTLA-2001 for ATTR. Read our buy thesis on NTLA stock here.

NTLA-2002 is designed to prevent HAE attacks by inactivating the kallikrein B1 (KLKB1) gene, which encodes for prekallikrein, the kallikrein precursor protein.

NTLA-2002 has been well tolerated at all dose levels Intellia to host investor webcast on Monday, June 12, at 8 a.m. ET ...

Priority programs – NTLA-2002 for hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) for transthyretin (ATTR) amyloidosis – set foundation for significant, near-term value creation ...